Home » Evusheld Likely Not Effective Against Omicron, FDA Says
Evusheld Likely Not Effective Against Omicron, FDA Says
October 5, 2022
The FDA has updated its fact sheet for healthcare providers for the use of AstraZeneca’s Evusheld (tixagevimab co-packaged with cilgavimab) which is authorized for emergency use for treatment of COVID-19 infections.
The agency warned that the injectable treatment might not be able to neutralize certain SARS-CoV-2 viral variants and that Evusheld might not be effective at preventing COVID-19 caused by the variants.
Of particular concern is the BA.4.6 form of Omicron, which has shown reduced susceptibility to the drug.
Evusheld is currently authorized for the pre-exposure prophylaxis of COVID-19 in adults and pediatric individuals 12 years of age and older weighing at least 40 kilograms (88 pounds).
Upcoming Events
-
21Oct